IN185119B - - Google Patents

Info

Publication number
IN185119B
IN185119B IN723DE1996A IN185119B IN 185119 B IN185119 B IN 185119B IN 723DE1996 A IN723DE1996 A IN 723DE1996A IN 185119 B IN185119 B IN 185119B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Edib Jakupovic
Jan Trofast
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20397958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN185119(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of IN185119B publication Critical patent/IN185119B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IN723DE1996 1995-04-13 1996-04-02 IN185119B (cg-RX-API-DMAC7.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501384A SE9501384D0 (sv) 1995-04-13 1995-04-13 Process for the preparation of respirable particles

Publications (1)

Publication Number Publication Date
IN185119B true IN185119B (cg-RX-API-DMAC7.html) 2000-11-18

Family

ID=20397958

Family Applications (1)

Application Number Title Priority Date Filing Date
IN723DE1996 IN185119B (cg-RX-API-DMAC7.html) 1995-04-13 1996-04-02

Country Status (22)

Country Link
US (1) US6221398B1 (cg-RX-API-DMAC7.html)
EP (1) EP0820276B1 (cg-RX-API-DMAC7.html)
JP (1) JPH11503448A (cg-RX-API-DMAC7.html)
CN (1) CN1102383C (cg-RX-API-DMAC7.html)
AR (1) AR001624A1 (cg-RX-API-DMAC7.html)
AT (1) ATE230257T1 (cg-RX-API-DMAC7.html)
AU (1) AU694863B2 (cg-RX-API-DMAC7.html)
CA (1) CA2217062A1 (cg-RX-API-DMAC7.html)
DE (1) DE69625589T2 (cg-RX-API-DMAC7.html)
DK (1) DK0820276T3 (cg-RX-API-DMAC7.html)
ES (1) ES2188750T3 (cg-RX-API-DMAC7.html)
IL (1) IL117841A (cg-RX-API-DMAC7.html)
IN (1) IN185119B (cg-RX-API-DMAC7.html)
MY (1) MY117344A (cg-RX-API-DMAC7.html)
NO (1) NO316209B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ305515A (cg-RX-API-DMAC7.html)
PT (1) PT820276E (cg-RX-API-DMAC7.html)
SA (1) SA96160645B1 (cg-RX-API-DMAC7.html)
SE (1) SE9501384D0 (cg-RX-API-DMAC7.html)
TW (1) TW492877B (cg-RX-API-DMAC7.html)
WO (1) WO1996032095A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA962596B (cg-RX-API-DMAC7.html)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
SE9701956D0 (sv) 1997-05-23 1997-05-23 Astra Ab New composition of matter
SK184799A3 (en) * 1997-06-27 2000-06-12 Astra Ab New combination of antiasthma medicaments
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
GB9806477D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved crystals
GB2341120B (en) 1998-09-04 2002-04-17 Aea Technology Plc Controlling uniformity of crystalline precipitates
SE9803770D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
SE9804001D0 (sv) * 1998-11-23 1998-11-23 Astra Ab New process
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
GB9905512D0 (en) * 1999-03-10 1999-05-05 Smithkline Beecham Plc Process
GB9919693D0 (en) * 1999-08-19 1999-10-20 Rhone Poulenc Rorer Ltd Process
CZ20011726A3 (cs) 2000-05-26 2002-02-13 Pfizer Products Inc. Způsob reakční krystalizace, který umoľňuje řídit velikost částic
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
CA2445146A1 (en) 2001-05-05 2002-11-14 Accentus Plc Formation of small crystals
DE10137017A1 (de) * 2001-07-30 2003-02-20 Basf Ag Kristallisationsverfahren zur Einstellung kleiner Partikel
WO2003032951A1 (en) * 2001-08-29 2003-04-24 Dow Global Technologies Inc. A process for preparing crystalline drug particles by means of precipitation
MXPA04002446A (es) * 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7931022B2 (en) * 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
EP1476201B1 (en) * 2002-02-19 2008-12-24 Resolution Chemicals Limited Solvent-based sterilisation of steroids
DE10214031A1 (de) * 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
FI20020857A7 (fi) * 2002-05-07 2003-11-08 Focus Inhalation Oy Amorfisen aineen muuntaminen vastaavaksi kiteiseksi aineeksi spraykuivaamalla ja käyttämällä kiteistä spraykuivattua ainetta lääkevalmisteissa
EP1531794B1 (en) * 2002-06-28 2017-05-10 Civitas Therapeutics, Inc. Inhalable epinephrine
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040028746A1 (en) * 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20060241130A1 (en) * 2003-01-31 2006-10-26 Ehud Keinan Anti-inflammatory compositions and uses thereof
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1610878B1 (en) * 2003-02-21 2014-09-03 University Of Bath Process for the production of particles
US7041144B2 (en) * 2003-03-04 2006-05-09 Five Star Technologies, Inc. Hydrodynamic cavitation crystallization process
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
KR20060006949A (ko) * 2003-04-29 2006-01-20 아크조 노벨 엔.브이. 반용매 고화 방법
US20060275219A1 (en) * 2003-06-10 2006-12-07 Taisho Pharmaceutical Co., Ltd. Radial spherical crystallization product, process for producing the same, and dry powder preparation containing the crystallization product
SE0302029D0 (sv) * 2003-07-07 2003-07-07 Astrazeneca Ab Novel process
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
JP2007520555A (ja) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005105278A2 (en) * 2004-05-05 2005-11-10 Akzo Nobel N.V. Antisolvent emulsion solidification process
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
EP1753734A1 (en) * 2004-05-05 2007-02-21 Renopharm Ltd. Nitric oxide donors and uses thereof
US8134010B2 (en) * 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
US7968575B2 (en) * 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
US20060009435A1 (en) * 2004-06-23 2006-01-12 Joseph Kaspi Synthesis and powder preparation of fluticasone propionate
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
WO2006045795A2 (en) * 2004-10-29 2006-05-04 Akzo Nobel N.V. Processes involving the use of antisolvent crystallization
US20060120972A1 (en) * 2004-11-09 2006-06-08 Peter Engels 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension
DE102005011786A1 (de) 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
CN101312713A (zh) * 2005-03-18 2008-11-26 纳米材料科技有限公司 可吸入的药物
WO2006113309A1 (en) 2005-04-15 2006-10-26 Dr. Reddy's Laboratories Ltd. Lacidipine particles
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
AU2006272438B2 (en) * 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
CN101262846A (zh) * 2005-07-15 2008-09-10 Map药物公司 在离散的吸入粒子中结合的多种活性药物成分及其制剂
EP1912730A2 (en) * 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
AU2006315177A1 (en) * 2005-11-15 2007-05-24 Baxter Healthcare S.A. Compositions of lipoxygenase inhibitors
WO2007070843A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US20070178166A1 (en) * 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2008057048A1 (en) * 2006-11-09 2008-05-15 Nanomaterials Technology Pte Ltd Nano & micro-sized particles of statin compounds and process for forming same
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
EP2191821A1 (en) * 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation
EP3620154A1 (en) * 2009-02-06 2020-03-11 University Of Southern California Therapeutic compositions comprising monoterpenes
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US20100298602A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Systems and methods for microfluidic crystallization
US20100294986A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Supercritical fluid facilitated particle formation in microfluidic systems
SG178036A1 (en) 2009-07-15 2012-03-29 Theravance Inc Crystalline freebase forms of a biphenyl compound
CN102573886A (zh) * 2009-09-17 2012-07-11 相互制药公司 用抗病毒剂治疗哮喘的方法
KR20150043548A (ko) 2009-10-01 2015-04-22 앱탈리스 파마테크, 인코포레이티드 경구 투여용 코르티코스테로이드 조성물
CN102711743A (zh) 2009-10-22 2012-10-03 Api起源有限责任公司 含有黄酮类的组合物的制备和使用方法
CN104744215B (zh) 2010-03-03 2019-03-15 尼昂克技术公司 包含单萜的药物组合物
CN101849910B (zh) * 2010-05-18 2012-02-22 重庆华邦制药股份有限公司 一种二丙酸倍他米松微粒的制备方法
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
US9499461B2 (en) 2010-08-27 2016-11-22 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives
AU2011305566A1 (en) 2010-09-22 2013-05-02 Map Pharmaceuticals, Inc. Aerosol composition for administering drugs
ES3056006T3 (en) 2010-12-17 2026-02-17 Univ Southern California Methods and devices for using isoperillyl alcohol
CN102134236B (zh) * 2011-04-15 2013-07-24 北方民族大学 微细克拉霉素粉体的制备方法
EP2729480A4 (en) * 2011-07-08 2014-12-31 Pfizer Ltd PROCESS FOR THE PREPARATION OF FLUTICASONE PROPIONATE, FORM 1
KR102017915B1 (ko) 2011-10-11 2019-09-03 키에시 파르마슈티시 엣스. 피. 에이. 지방산으로 코팅된 베타-작용제의 결정미세입자
DE102012221219B4 (de) * 2012-11-20 2014-05-28 Jesalis Pharma Gmbh Verfahren zur Vergrößerung der Partikelgröße kristalliner Wirkstoff-Mikropartikel
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
ES2773142T3 (es) 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
CA2954287C (en) * 2014-07-08 2020-12-22 Amphastar Pharmaceuticals, Inc. Methods of preparing inhalable micronized insulin for pulmonary delivery
WO2016130800A2 (en) 2015-02-12 2016-08-18 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
US10322168B2 (en) 2016-01-07 2019-06-18 Amphastar Pharmaceuticals, Inc. High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
JP7325425B2 (ja) 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク. 血液脳関門を透過性にする方法
WO2020205539A1 (en) 2019-03-29 2020-10-08 Vizuri Health Sciences Consumer Healthcare, Inc. Compositions and methods for the prevention and treatment of radiation dermatitis, eczema, burns, wounds and certain cancers
US12691128B2 (en) 2019-10-01 2026-07-28 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and reducing candidiasis
CN114262316A (zh) * 2021-12-24 2022-04-01 嘉应学院 纳米橙皮素、其制备方法及所用双匀浆空化射流系统
CN117582373A (zh) * 2023-08-15 2024-02-23 中国药科大学 一种类球形无载体妥布霉素粉雾剂颗粒的湍流强化可控制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
DE68907062T2 (de) * 1988-10-05 1993-10-07 Upjohn Co Feinverteiltes feste kristalline pulver durch niederschlag in einem anti-lösungsmittel.
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles

Also Published As

Publication number Publication date
SA96160645B1 (ar) 2005-07-05
NO974557L (no) 1997-10-02
AU5352496A (en) 1996-10-30
IL117841A0 (en) 1996-08-04
CN1102383C (zh) 2003-03-05
MY117344A (en) 2004-06-30
ES2188750T3 (es) 2003-07-01
PT820276E (pt) 2003-04-30
ATE230257T1 (de) 2003-01-15
JPH11503448A (ja) 1999-03-26
NZ305515A (en) 1999-03-29
US6221398B1 (en) 2001-04-24
SE9501384D0 (sv) 1995-04-13
DE69625589D1 (de) 2003-02-06
EP0820276A1 (en) 1998-01-28
AU694863B2 (en) 1998-07-30
ZA962596B (en) 1996-10-14
CA2217062A1 (en) 1996-10-17
AR001624A1 (es) 1997-11-26
EP0820276B1 (en) 2003-01-02
IL117841A (en) 2004-01-04
CN1186428A (zh) 1998-07-01
NO316209B1 (no) 2003-12-29
DK0820276T3 (da) 2003-03-17
WO1996032095A1 (en) 1996-10-17
DE69625589T2 (de) 2003-09-25
TW492877B (en) 2002-07-01
NO974557D0 (no) 1997-10-02

Similar Documents

Publication Publication Date Title
BR122012014331A2 (cg-RX-API-DMAC7.html)
BRPI9612138B1 (cg-RX-API-DMAC7.html)
EP0825907A4 (cg-RX-API-DMAC7.html)
GB9503866D0 (cg-RX-API-DMAC7.html)
CH0741373H1 (cg-RX-API-DMAC7.html)
BR7502120U (cg-RX-API-DMAC7.html)
IN182659B (cg-RX-API-DMAC7.html)
IN183946B (cg-RX-API-DMAC7.html)
IN186621B (cg-RX-API-DMAC7.html)
IN182677B (cg-RX-API-DMAC7.html)
IN182319B (cg-RX-API-DMAC7.html)
IN186172B (cg-RX-API-DMAC7.html)
CN3035539S (cg-RX-API-DMAC7.html)
CN3034896S (cg-RX-API-DMAC7.html)
CN3030489S (cg-RX-API-DMAC7.html)
EP0863823A4 (cg-RX-API-DMAC7.html)
EP0766265A3 (cg-RX-API-DMAC7.html)
BY5258C1 (cg-RX-API-DMAC7.html)
CN3030542S (cg-RX-API-DMAC7.html)
CN3034473S (cg-RX-API-DMAC7.html)
CN3035871S (cg-RX-API-DMAC7.html)
CN3034829S (cg-RX-API-DMAC7.html)
CN3031350S (cg-RX-API-DMAC7.html)
CN3035870S (cg-RX-API-DMAC7.html)
CN3034189S (cg-RX-API-DMAC7.html)